<DOC>
	<DOCNO>NCT00115245</DOCNO>
	<brief_summary>This research study conduct compare safety effectiveness investigational medication , LdT ( telbivudine ) versus adefovir dipivoxil , drug approve Food Drug Administration ( FDA ) treatment hepatitis B infection . The result patient take LdT compare result patient take adefovir dipivoxil .</brief_summary>
	<brief_title>Telbivudine Versus Adefovir Dipivoxil Adults With HBegAg-Positive , Compensated Chronic Hepatitis B</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Telbivudine</mesh_term>
	<criteria>Documented compensate chronic hepatitis B define clinical history compatible compensate chronic hepatitis B Detectable serum HBsAg Screening visit Other protocoldefined inclusion criterion may apply . Patient pregnant breastfeeding . Patient coinfected hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) HIV Patient previously receive lamivudine , adefovir dipivoxil , investigational antihepatitis B virus ( HBV ) nucleoside nucleotide analog time Patient receive interferon immunomodulatory treatment HBV infection 12 month screen study Other protocoldefined exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>May 2015</verification_date>
</DOC>